Biohaven Pharmaceutical Holding Co Ltd (BHVN) — Cash Flow-to-Debt Ratio
Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a Cash Flow-to-Debt Ratio of -0.44x as of March 2026, meaning its operating cash flow of $-149.92 Million could theoretically repay 0% of its total liabilities ($336.91 Million) in one year. See Biohaven Pharmaceutical Holding Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Biohaven Pharmaceutical Holding Co Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Biohaven Pharmaceutical Holding Co Ltd across 9 annual periods. Also explore BHVN net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
Year-by-year debt coverage analysis for Biohaven Pharmaceutical Holding Co Ltd. For market capitalisation and broader financial context, see market value of Biohaven Pharmaceutical Holding Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.53x | $-609.44 Million | $399.38 Million | ▲ +49.8% |
| 2024 | -3.04x | $-582.45 Million | $191.67 Million | ▲ +21.9% |
| 2023 | -3.89x | $-331.73 Million | $85.24 Million | ▼ -60.8% |
| 2022 | -2.42x | $-297.69 Million | $123.01 Million | ▲ +21.4% |
| 2021 | -3.08x | $-145.84 Million | $47.37 Million | ▼ -40.7% |
| 2020 | -2.19x | $-75.96 Million | $34.72 Million | ▼ -103.9% |
| 2019 | -1.07x | $-377.33 Million | $351.69 Million | ▲ +24.3% |
| 2018 | -1.42x | $-197.14 Million | $139.09 Million | ▲ +77.7% |
| 2017 | -6.36x | $-94.81 Million | $14.92 Million | — |